Top 5 Electric Utility Stocks To Invest In 2016

Top 5 Electric Utility Stocks To Invest In 2016: Adamis Pharmaceuticals Corp (ADMP)

Adamis Pharmaceuticals Corporation (Adamis), formerly Cellegy Pharmaceuticals, Inc., incorporated on April 22, 2004, operates through its wholly owned subsidiaries Cellegy Holdings, Inc., Adamis Corporation and Biosyn, Inc. Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc. (Adamis Viral) and Adamis Laboratories, Inc. (Adamis Labs). Adamis Labs is a specialty pharmaceutical company. The Company focuses on the development of preventive and therapeutic vaccine products and cancer drugs for patients with unmet medical needs. Adamis focuses on developing and commercializing products in the anti-inflammatory, allergy and respiratory field that are commercialized by the Company. Additional product candidates in its allergy and respiratory product pipeline include a steroid HFA (hydrofluoroalkane) metered dose inhaler product, referred to as APC-1000, for asthma and chronic obstructive pulmonary disease (COPD); a generic High-functioning autism (HF A) bronchodilator, referred to as APC-2000; and an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis, referred to as APC-3000.

Adamis Labs' product pipeline includes the single dose-epinephrine PFS syringe product and an inhaled nasal steroid product candidate, and additional asthma and allergy products. Adamis Labs is developing an aerosolized inhaled nasal steroid product, which it referred to as APC-3000, for the treatment of seasonal and perennial allergic rhinitis. The Company's Adamis Viral subsidiary is focused on the development of Adamis' therapeutic vaccine product candidates and prostate cancer drugs for prostate cancer patients.

Drug Product Candidates in Development

APC-100 is an anti-inflammatory drug candidate. In animal studies, ! APC-100 demonstrated potent anti-androgenic and anti-inflammatory activities against prostate tumors growing in animal models and sh owed a safety profile in preclinical safety studies. APC-100! has demonstrated pharmacological characteristics as an oral or injectable anti-inflammatory and anti-androgenic drug candidate with multiple mechanisms of action. APC-100 decreases secretion of human Prostate Specific Antigen (PSA), by human prostate cancer cells growing in mice and also increases the time-to-tumor progression and survival of PCa mice with CS-PCa and CR-PCa tumors.

APC-200 is a drug candidate for both castrate-sensitive and castrate resistant prostate cancer. APC-200 blocks androgen-induced hydrogen peroxide production and inflammation and inhibits mouse PCa. In animal studies, APC-200 was an inhibitor of chronic inflammation, also completely inhibiting oxidase mediated high rates of hydrogen peroxide. APC-200 is developed as an oral drug, specifically in appropriate formulations for patients with PCa.

APC-300 is a multi-targeted small molecule therapeutic drug, which demonstrates anti-inflammatory, pro-apoptotic anti-cancer activ ities for prostate cancer patients, including men with metastatic CR-PCa. In pre-clinical in vivo studies conducted, APC-300 demonstrated the ability to inhibit human tumor growth and kill both castrate-sensitive and castrate-resistant human prostate cancer tumors. It also decreased human tumor volumes and suppressed local metastasis in human xenograft models, where malignant human prostate or human melanoma tumor tissue was grafted onto athymic immunosuppressed experimental mice. APC-300 inhibited human androgen receptor protein production in these studies. It also inhibited PSA secretion by human PCa cells, which is a serum marker for human prostate cancer.

The Company competes with Medivation, TEVA Pharmaceutical Industries Ltd and AstraZeneca.

Advisors' Opinion:

• [By Bryan Murphy]

  Although th! e market ! seems to be losing traction, and even losing ground now, the same can't be said of every single stock. A handful of stocks like China Jo-Jo Drugstores Inc. (NASDAQ:CJJD), Vuzix Corp. (OTCBB:VUZI), and Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) are forging ahead, doling out gains against the grain. Not that moving higher while other names are moving lower is a sure sign that ADMP, VUZI, and CJJD will remain in their uptrends indefinitely, but it sure doesn't hurt their odds. Here's a closer look at each one and why you'd want to add them to your watchlist.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-electric-utility-stocks-to-invest-in-2016.html